Hebrew University of Jerusalem
Researchers at the Hebrew University of Jerusalem discovered a method to potentially eliminate the tumor-risk factor in utilizing human embryonic stem cells, said the university on Wednesday.
The researchers’ work paves the way for further progress in the promising field of stem cell therapy, said the press release of the university sent to Xinhua.
According to the release, human embryonic stem cells are theoretically capable of differentiation to all cells of the mature human body (and are hence defined as “pluripotent“).
This ability, along with the ability to remain undifferentiated indefinitely in culture, make regenerative medicine using human
Joseph Wagner sees most cell-therapy companies offering little more than a bag of cells.
His company will give the bag a little direction.
Cell Targeting is developing technology that can point stem cell therapies to specific areas of the body. Among the many challenges in cell therapy is direction: not enough of the stem cells are getting to the tissues that needs treatment (…)
Currently a stem cell therapy can help different parts of the body. That attracts more customers, but doesn’t do much when the company wants to differentiate its product and charge a different price.
A stem cell therapy tweaked by
Reviewing the technology, business models, intellectual property, regulatory concerns, transplantation and immune rejection.
CD133 (Prominin) is widely used as a marker for the identification and isolation of neural precursor cells from normal brain or tumor tissue. However, the assumption that CD133 is expressed constitutively in neural precursor cells has not been examined.
In this study, we demonstrate that CD133 and a second marker CD15 are expressed heterogeneously in uniformly undifferentiated human neural stem (NS) cell cultures. After fractionation by flow cytometry, clonogenic tripotent cells are found in populations negative or positive for either marker. We further show that CD133 is down-regulated at the mRNA level in cells lacking CD133 immunoreactivity. Cell cycle
Spinal cord injuries, resulting in permanent disability or paralysis in most cases, account for around eleven thousand new cases in the US, annually. Due to the lack of effective treatment strategies, it is considered as the most devastating of all traumatic conditions. Now, a recent study published in the journal Stem Cells reports that activation of ependymal stem/progenitor cells from injured spinal cord (epSPCi), using endogenous stem cell-associated mechanisms, may aid in rescuing neurological function, thereby reversing paralysis associated with spinal cord injuries.